Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8556 GBX | +0.66% | +3.71% | +0.66% |
Apr. 18 | N4 Pharma sees potential in Nuvec delivery method for cancer treatment | AN |
Apr. 18 | N4 Pharma’s In Vivo Testing Shows Nuvec’s Potential as Oral Delivery System | MT |
Sales 2021 | - | Sales 2022 | - | Capitalization | 4.32M 5.35M |
---|---|---|---|---|---|
Net income 2021 | -1M -1.24M | Net income 2022 | -1M -1.24M | EV / Sales 2021 | - |
Net cash position 2021 | 1.78M 2.21M | Net cash position 2022 | 1.92M 2.37M | EV / Sales 2022 | - |
P/E ratio 2021 |
-5.22
x | P/E ratio 2022 |
-3.35
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 77.72% |
Latest transcript on N4 Pharma Plc
1 day | +0.66% | ||
1 week | +3.71% | ||
Current month | +31.63% | ||
1 month | +26.76% | ||
3 months | -7.50% | ||
6 months | -9.94% | ||
Current year | +0.66% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 59 | 13-12-31 | |
David Templeton
CTO | Chief Tech/Sci/R&D Officer | - | 17-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 46 | 20-07-13 | |
Founder | 59 | 13-12-31 | |
Chris Britten
CHM | Chairman | - | 19-05-19 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 0.8556 | +0.66% | 1 713 806 |
24-04-22 | 0.85 | 0.00% | 849,442 |
24-04-19 | 0.85 | 0.00% | 119,308 |
24-04-18 | 0.85 | +3.03% | 653,092 |
24-04-17 | 0.825 | 0.00% | 135,677 |
Delayed Quote London S.E., April 23, 2024 at 03:22 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+0.66% | 2.82M | |
+25.46% | 659B | |
+25.73% | 557B | |
-4.86% | 359B | |
+16.44% | 322B | |
+8.34% | 297B | |
+6.40% | 215B | |
+7.85% | 210B | |
-5.93% | 200B | |
-8.79% | 149B |
- Stock Market
- Equities
- ONZ Stock